Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma.
Lenalidomide, a recently developed immunomodulatory drug, shares the antiangiogenic and antitumor properties of thalidomide. While there is a known association between thalidomide and hypothyroidism, to our knowledge, there have been no prior reports of thyrotoxicosis associated with thalidomide or lenalidomide treatment. Herein, we report the case of a patient who developed transient thyrotoxicosis while receiving lenalidomide in a clinical trial for metastatic renal cell carcinoma. The time course and biochemical features of this patient's presentation are most consistent with immune-mediated subacute destructive thyroiditis. This case highlights the importance of monitoring thyroid function in the growing number of patients being treated with lenalidomide.
Stein
Emily M
EM
Department of Medicine/Endocrinology, Weill Medical College of Cornell University, New York, New York 10021, USA. ems9004@med.cornell.edu
Rivera
Cristina
C
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077269:Lenalidomide; D008297:Male; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000633:toxicity; D013960:Thyroid Function Tests; D013966:Thyroiditis / Q000139:chemically induced; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide